TScan Therapeutics (TCRX) Competitors

TScan Therapeutics (NASDAQ:TCRX) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, community ranking, dividends, valuation and earnings.

Which has higher valuation and earnings, TCRX or NGNE?

Neurogene has lower revenue, but higher earnings than TScan Therapeutics. Neurogene is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$4.42M	16.32	-$89.22M	-$1.09	-1.17
Neurogene	$925K	272.52	-$36.32M	-$4.35	-4.06

Do analysts prefer TCRX or NGNE?

TScan Therapeutics presently has a consensus target price of $7.80, suggesting a potential upside of 511.76%. Neurogene has a consensus target price of $44.60, suggesting a potential upside of 152.33%. Given TScan Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe TScan Therapeutics is more favorable than Neurogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Neurogene	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Is TCRX or NGNE more profitable?

Neurogene has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,188.88%. Neurogene's return on equity of -32.81% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,188.88%	-58.72%	-36.02%
Neurogene	N/A	-32.81%	-27.96%

Do institutionals & insiders have more ownership in TCRX or NGNE?

82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 52.4% of Neurogene shares are owned by institutional investors. 2.8% of TScan Therapeutics shares are owned by insiders. Comparatively, 9.9% of Neurogene shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Which has more volatility & risk, TCRX or NGNE?

TScan Therapeutics has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500.

Does the media refer more to TCRX or NGNE?

In the previous week, Neurogene had 24 more articles in the media than TScan Therapeutics. MarketBeat recorded 24 mentions for Neurogene and 0 mentions for TScan Therapeutics. TScan Therapeutics' average media sentiment score of 1.06 beat Neurogene's score of 0.29 indicating that TScan Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
TScan Therapeutics	Positive
Neurogene	Neutral

Does the MarketBeat Community prefer TCRX or NGNE?

TScan Therapeutics received 12 more outperform votes than Neurogene when rated by MarketBeat users. However, 91.18% of users gave Neurogene an outperform vote while only 84.31% of users gave TScan Therapeutics an outperform vote.

Company	Underperform	Outperform
TScan Therapeutics	Outperform Votes 43 84.31%	Underperform Votes 8 15.69%
Neurogene	Outperform Votes 31 91.18%	Underperform Votes 3 8.82%

Summary

Neurogene beats TScan Therapeutics on 9 of the 17 factors compared between the two stocks.